The administration of recombinant human VEGF exacerbated the formation of AAAs in Ang II-infused mice and increased the maximum aortic diameter and cross-sectional area of aneurysms, while treatment with VEGF increased MMP-2 gene expression in the aortic wall in Ang II-infused mice108. The gene discussed is AGT; the disease is achalasia-alacrima syndrome.